Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24034836 | 0.86 | GRM2 (0.41) | MAPK14GRM2SIGMAR1 | |
| SCHEMBL24034845 | 0.83 | HSD11B1 (0.43) | GRM2 | |
| SCHEMBL30111784 | 0.83 | HSD11B1 (0.43) | GRM2 | |
| SCHEMBL2687426 | 0.82 | DHODH (0.38) | TP53 | |
| SCHEMBL2687825 | 0.78 | CSNK1D (0.43) | NPC1RAB9AMAPK14CSNK1DCSNK1E | |
| SCHEMBL26134747 | 0.77 | DPP4 (0.36) | DPP4NPC1RAB9AMAPK14TP53 | |
| SCHEMBL15543675 | 0.75 | CCNC (0.41) | MAPK14GCGRGRM5 | |
| SCHEMBL2689815 | 0.73 | TRPV3 (0.36) | MAPK14CSNK1DCSNK1EGRM5SLC34A1 | |
| SCHEMBL28906200 | 0.72 | ALPL (0.48) | NPC1RAB9AMAPK14GRM5SLC34A1 | |
| SCHEMBL31617643 | 0.70 | SLC34A1 (0.42) | DPP4GRM5SLC34A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149933-B1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2024-06-12 | — | — | EP | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4149933-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-22 | — | — | EP | disclosed |
| CN-115461337-A | Novel triazolyl derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021228795-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRA3, GABRB3 | DPP4 1724/4885NPC1 2135/4885RAB9A 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.